Synapse - Andrew Seidman

Results (318)

A summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene Recurrence Score (R) (RS) assay and other genomic assays for early breast cancer (EBC)

Meeting Abstract

Varga, Z.; McCullough, D.; Lau, A.; Stoppler, M.; Baehner, F. L.; Seidman, A. D.
Breast (2017)

Fulltext@MSK | Save

Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis

Journal Article

Morikawa, A.; Jordan, L.; Rozner, R.; Patil, S.; Boire, A.; Pentsova, E.; Seidman, A. D.
Clinical Breast Cancer (2017)

Fulltext@MSK | Save

Treatment options of long term survivors with leptomeningeal metastases and breast cancer

Meeting Abstract

Chaul-Barbosa, C.; Morikawa, A.; Patil, S.; Boire, A.; Jordan, L.; Rozner, R.; Seidman, A.; Pentsova, E.
Neuro-Oncology (2016)

Fulltext@MSK | Save

Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk

Journal Article

Bao, T.; Basal, C.; Seluzicki, C.; Li, S. Q.; Seidman, A. D.; Mao, J. J.
Breast Cancer Research and Treatment (2016)

Fulltext@MSK | Save

When to combine endocrine therapy with a new agent for hormone receptor-positive metastatic breast cancer in postmenopausal women

Journal Article

Seidman, A. D.
Oncology (Norwalk) (2016)

Fulltext@MSK | Save

Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer

Meeting Abstract

Cadoo, K.; Kaufman, P. A.; Hudis, C.; Chang, C.; Berrak, E.; Song, J.; Seidman, A. D.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling

Meeting Abstract

Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
Cancer Research (2016)

Fulltext@MSK | Save

Integration of multi-modality treatment planning for early stage breast cancer (BC) into Watson for Oncology, a Decision Support System: Seeing the forest and the trees